Abstract
Background: Aldo-keto reductase 1C3 (AKR1C3) is an important oxidoreductase with multiple substrates, that are involved in producing extra-testicular androgens. Its activity is influenced by environmental exposures, as well as by genetic variants. These genetic variants could therefore produce variable testosterone levels and subsequent androgen receptor (AR) activation. This could lead to differential downstream production of the prostate-specific antigen (PSA). As PSA level is used for clinical evaluation of the prostate, these variations could impact prostate cancer (PC) diagnosis, as well as PC management outcomes. This review brings together information with regards to key functions of this enzyme, its relevance in PC, its transcriptional regulation, clinical aspects associated with genetics, differential regulation in cancer and cancer progression, and the types of AKR1C3 inhibitors with future therapeutic value.
Conclusion: Based on these discussions, hypotheses are forwarded for future applicability of this enzyme and its genetic variants in transformational medical practices in PC. Options for the use of personalised AKR1C3 inhibitor drugs for late stage PC are also discussed.Keywords: AKR1C3 rs12529, extra-testicular androgen, prostate-specific antigen (PSA), prostate cancer (PC), cancer progression, androgen deprivation therapy (ADT), AKR1C3 inhibitors.
Current Cancer Drug Targets
Title:Influence of Aldo-keto Reductase 1C3 in Prostate Cancer - A Mini Review
Volume: 17 Issue: 7
Author(s): Nishi Karunasinghe*, Jonathan Masters, Jack U. Flanagan and Lynnette R. Ferguson
Affiliation:
- Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland 1142,New Zealand
Keywords: AKR1C3 rs12529, extra-testicular androgen, prostate-specific antigen (PSA), prostate cancer (PC), cancer progression, androgen deprivation therapy (ADT), AKR1C3 inhibitors.
Abstract: Background: Aldo-keto reductase 1C3 (AKR1C3) is an important oxidoreductase with multiple substrates, that are involved in producing extra-testicular androgens. Its activity is influenced by environmental exposures, as well as by genetic variants. These genetic variants could therefore produce variable testosterone levels and subsequent androgen receptor (AR) activation. This could lead to differential downstream production of the prostate-specific antigen (PSA). As PSA level is used for clinical evaluation of the prostate, these variations could impact prostate cancer (PC) diagnosis, as well as PC management outcomes. This review brings together information with regards to key functions of this enzyme, its relevance in PC, its transcriptional regulation, clinical aspects associated with genetics, differential regulation in cancer and cancer progression, and the types of AKR1C3 inhibitors with future therapeutic value.
Conclusion: Based on these discussions, hypotheses are forwarded for future applicability of this enzyme and its genetic variants in transformational medical practices in PC. Options for the use of personalised AKR1C3 inhibitor drugs for late stage PC are also discussed.Export Options
About this article
Cite this article as:
Karunasinghe Nishi *, Masters Jonathan , Flanagan U. Jack and Ferguson R. Lynnette, Influence of Aldo-keto Reductase 1C3 in Prostate Cancer - A Mini Review, Current Cancer Drug Targets 2017; 17 (7) . https://dx.doi.org/10.2174/1568009617666170330115722
DOI https://dx.doi.org/10.2174/1568009617666170330115722 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
The Impact of Cancer Neuroscience on Novel Brain Cancer Treatment
Brain cancer remains one of the most challenging malignancies due to its complexity and resistance to conventional therapies. Recent advancements in cancer neuroscience have transformed our understanding of the brain's tumor microenvironment, offering promising insights into novel treatments. By studying the intricate interactions between cancer cells and the nervous system, ...read more
Unraveling the Tumor Microenvironment and Potential Therapeutic Targets: Insights from Single-Cell Sequencing and Spatial Transcriptomics
This special issue will focus on unraveling the complexities of the tumor microenvironment (TME) and identifying key biomarkers for potential therapeutic targets using advanced multi-omics techniques, such as single-cell sequencing and spatial transcriptomics. We seek original research and comprehensive reviews that investigate the heterogeneity and dynamics of the TME, emphasizing ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MSD-MAP: A Network-Based Systems Biology Platform for Predicting Disease-Metabolite Links
Combinatorial Chemistry & High Throughput Screening Antiangiogenic Therapy
Current Pharmaceutical Design The Medicinal Chemistry of Therapeutic Peptides: Recent Developments in Synthesis and Design Optimizations
Current Medicinal Chemistry Editorial (Hot Topic: Androgen Receptor and Prostate Cancer: New Insights in an Old Target Translate into Novel Therapeutic Strategies)
Current Drug Targets Genito-Urological Cancers in Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Three Amino Acid Derivatives of Valproic Acid: Design, Synthesis, Theoretical and Experimental Evaluation as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry An Update On Proficiency of Voltage-gated Ion Channel Blockers in the Treatment of Inflammation-associated Diseases
Current Drug Targets Content Analysis, Cytotoxic, and Anti-metastasis Potential of Bioactive Polysaccharides from Green Alga <i>Codium intricatum</i> Okamura
Current Bioactive Compounds Role of Class II Nuclear Receptors in Liver Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Anti-cancer Drug Discovery: Update and Comparisons in Yeast, Drosophila, and Zebrafish
Current Molecular Pharmacology Therapeutic Benefits of <i>Piper nigrum</i>: A Review
Current Bioactive Compounds Heterocyclization of Thiophenes Derived from Estrone Followed by Cytotoxic, HTRF Kinase and Pim-1 Kinase Evaluations
Anti-Cancer Agents in Medicinal Chemistry The Role of Clusterin in Carcinogenesis and its Potential Utility as Therapeutic Target
Current Medicinal Chemistry <i>In vivo</i>, <i>in vitro</i> and Molecular Modelling Analysis of Isoquercetin, Roseoside, Coreximine, Anonaine, and Arianacin Molecules
Current Computer-Aided Drug Design A Rationale for Inhibiting Progesterone-Related Pathways to Combat Breast Cancer
Current Cancer Drug Targets Overlooked Issues of Snakebite Management: Time for Strategic Approach
Current Topics in Medicinal Chemistry Extraction, Chemical Composition, Antioxidant Property, and <i>In-vitro</i> Anticancer Activity of Silymarin from <i>Silybum marianum</i> on Kb and A549 Cell Lines
Current Drug Discovery Technologies Recent Progress in Andrographolide Derivatization: Structural Modification and Biological Activity
Mini-Reviews in Medicinal Chemistry Stem Cells: Therapeutic Implications in Chemotherapy and Radiotherapy Resistance in Cancer Therapy
Current Stem Cell Research & Therapy Effect of Electric Field Intensity on Plasmid DNA/Membrane Interaction during In-Vitro Gene Electrotransfer
Drug Delivery Letters